Spatial biology is rapidly developing in both the number of cell types it can characterise and in its ability, to directly detect the therapeutic agent in situ. Here we demonstrate two novel technologies that address key unmet needs:

Target validation of therapeutic antibodies (TxAb) by IHC is a challenge because classical anti-human detection methods cannot discriminate between donor antibodies and the TxAb. Direct conjugation to PhenoCode™ barcodes is a solution for single marker detection but PhenoCode™ panels that can incorporate it are less flexible in the markers that can be used. Here we develop a method to blend flexible Opal classic panels with PhenoCode™ technology to address this issue.

Inaccurate phenotyping of cells expressing proteins that diffuse away from the origin (e.g. cytokines) can be a challenge. Here we show an application of multiomic assays to identify cell types using both well characterized protein markers as well as cytokine RNA expression to ensure accurate cell phenotyping.